Why the study?
Does recombinant human erythropoietin affect pulmonary arterial pressure in uremic patients on hemodialysis?
Does recombinant human erythropoietin affect pulmonary arterial pressure in uremic patients on hemodialysis?
Recombinant human erythropoietin may have vasoactive effects that reduce pulmonary arterial pressure in hemodialysis patients, though mechanisms remain debated.
Answers are grounded in this paper and cite their sources.
Recombinant erythropoietin may reduce pulmonary pressure in hemodialysis; leaves open mechanisms and clinical relevance pending prospective trials.
Numerous uremic patients on hemodialysis have pulmonary hypertension attributable to the presence of arteriovenous fistulas, vascular calcification, and endothelial dysfunction due to alterations in the balance between vasoconstrictive and vasodilatory substances. For these reasons, the effects of recombinant human erythropoietin, a drug widely used in patients on dialysis, on the pulmonary circulation were studied. Some authors maintain that recombinant human erythropoietin has an antihypertensive effect, while others have observed that this hormone induces a reduction in pulmonary arterial pressure due to its vasoactive and stimulatory effects on endothelial and smooth muscle cell precursors.
No takes yet. Share an insight, caveat, or question.
Buemi et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: